Eurogentec

What we do: Eurogentec is an international biotechnology supplier based in Belgium, specializing in genomics and proteomics. The company offers a wide range of high-quality products and services to scientists in life science, biotechnology, diagnostics, and pharmaceutical markets. Its three business units focus on Life Science (including lab-scale and large-scale oligonucleotides, PCR/qPCR kits and reagents, peptides, antibodies, and assay kits), In Vitro Diagnostics (contract manufacturing of GMP oligonucleotides and Taq DNA polymerases), and Biomanufacturing (GMP production of proteins, plasmids, and vaccines for pre-clinical, clinical, and commercial use). Eurogentec is fully ISO 9001 and ISO 13485 certified, cGMP accredited by the Belgian Ministry of Health, and approved by the US FDA for commercial manufacturing of biologics for the US market.

Where we are located: Eurogentec’s headquarters is in Seraing, Liege, Belgium, at Rue du Bois Saint-Jean, 5, 4102. The company also operates production sites in Belgium, the UK, and the USA, supporting global customers with local expertise and logistics.

Short history: Founded in 1985, Eurogentec has grown into a leading global supplier of innovative reagents, kits, and custom services. Over the years, the company has expanded its capabilities in GMP manufacturing, fermentation, and molecular diagnostics, becoming part of Kaneka Corporation, a major international chemical company. Eurogentec’s expertise spans over three decades, marked by continuous innovation and a commitment to quality.

Organization & culture: Eurogentec is a trusted CDMO with a global presence, serving academia, diagnostic companies, and pharmaceutical industries. The company values a solution-oriented approach, individual support, and long-term partnerships. Its teams are highly skilled, regularly trained, and committed to maintaining the highest standards in quality management. Collaboration, expertise, and customer focus are central to Eurogentec’s culture.

Recent developments: Eurogentec recently completed commercial mRNA manufacturing, optimizing its IVT process to produce up to 50g of material per batch, suitable for late clinical and commercial use. The company continues to expand its GMP capabilities and product offerings, supporting the development of cutting-edge therapies and diagnostics worldwide.